Patients (n)
|
68
|
32
|
36
|
-
|
Age of initial treatment (years)
|
30.4 ± 3.9
|
31.0 ± 3.7
|
29.9 ± 4.1
|
0.272 a
|
Age of pregnancy permission (years)
|
31.9 ± 4.2
|
32.6 ± 3.8
|
31.2 ± 4.5
|
0.190 a
|
BMI c of initial treatment (kg/m2)
|
25.9 ± 4.2
|
26.9 ± 4.2
|
25.0 ± 3.9
|
0.051 a
|
BMI of pregnancy permission (kg/m2)
|
25.9 ± 3.8
|
27.2 ± 3.7
|
24.8 ± 3.6
|
0.007
|
Irregular menstrual cycle (%)
|
35 (51.5)
|
18 (56.2)
|
17 (47.2)
|
0.457 b
|
Infertility (%)
|
27 (39.7)
|
14 (43.8)
|
13 (36.1)
|
0.520b
|
Nulliparity (%)
|
62 (91.2)
|
30 (93.8)
|
32 (88.9)
|
0.481 b
|
Diabetes mellitus type 2 (%)
|
11 (16.2)
|
3 (9.4)
|
8 (22.2)
|
0.151 b
|
Insulin resistance (%)
|
21 (30.9)
|
10 (31.3)
|
11 (30.6)
|
0.950 b
|
High blood pressure (%)
|
6 (8.8)
|
2 (6.2)
|
4 (11.1)
|
0.481 b
|
Thyroid diseases (%)
|
9 (13.2)
|
4 (12.5)
|
5 (13.9)
|
0.866 b
|
Myometrium invasion in MRI (%)
|
16 (33.3)
|
8 (34.8)
|
8 (32.0)
|
0.581 b
|
PCO on ultrasonography (%)
|
37 (54.4)
|
20 (62.5)
|
17 (47.2)
|
0.207 b
|
PCOSd
|
27 (39.7)
|
13 (40.6)
|
14 (38.9)
|
0.884b
|
CA125 (U/mL)
|
22.4 ± 22.6
|
22.7 ± 16.2
|
22.2 ± 27.2
|
0.926 a
|
Histological type
| | | |
0.214 b
|
AEH
|
39
|
16
|
23
| |
EEC G1
|
21
|
10
|
11
| |
EEC G2
|
8
|
6
|
2
| |
Treatment protocol (%)
| | | |
0.831 b
|
MPA 250 mg, once daily
|
45 (67.2)
|
21 (65.6)
|
24 (68.6)
| |
MPA 500 mg, once daily
|
8 (11.9)
|
5 (15.6)
|
3 (8.6)
| |
MA 160-320 mg, once daily
|
9 (13.4)
|
4 (12.5)
|
5 (14.3)
| |
GnRH-a
|
5 (7.5)
|
2 (6.2)
|
3 (8.6)
| |
Adjuvant metformin (%)
|
25 (36.8)
|
15 (46.9)
|
10 (27.8)
|
0.103 b
|
Maintenance therapy (%)
| | | |
0.223 b
|
None
|
11 (16.2)
|
6 (18.8)
|
5 (13.9)
| |
Progestin
|
45 (66.2)
|
18 (56.2)
|
27 (75.0)
| |
LNG-IUD
|
12 (17.6)
|
8 (25.0)
|
4 (11.1)
| |
Conception method (%)
| | | |
0.246 b
|
Natural
|
19 (27.9)
|
12 (37.5)
|
7 (19.4)
| |
Ovulation induction ± IUI
|
9 (13.2)
|
4 (12.5)
|
5 (13.9)
| |
IVF-ET
|
40 (58.8)
|
16 (50.0)
|
24 (66.7)
| |